Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey
2 University Hospital of Cologne [Cologne]
3 Karolinska University Hospital [Stockholm]
4 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
5 KUH - Copenhagen University Hospital [Denmark] = Københavns Universitetshospital [Danmark]
6 UMCG - University Medical Center Groningen [Groningen]
7 Hospital Universitario HM Sanchinarro [Madrid, Spain]
8 IRCCS Ospedale San Raffaele [Milan, Italy]
9 University Hospital Brno
10 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
11 Openbare Bibliotheek Brugge
12 University of Zagreb
13 University of Rijeka
14 La Paz University Hospital
15 UNICA - Universidad de Ciego de Avila
16 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
17 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
18 VIB - Vlaams Instituut voor Biotechnologie = Flanders Institute for Biotechnology [Ghent]
19 Polytechnic University of Bari / Politecnico di Bari
20 Institute of Public Health of Republic of North Macedonia [Skopje]
21 University-Hospital Munich-Großhadern [München]
22 University of Debrecen
23 ICB - Istituto di chimica biomolecolare [Padova, Italy]
24 University of Szeged [Szeged]
25 UNAV - Universidad de Navarra [Pamplona]
26 Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan]
27 University of Athens Medical School [Athens]
28 UCA - Pontificia Universidad Católica Argentina (Universidad Católica Argentina) [Buenos Aires, Argentina] = Pontifical Catholic University of Argentina = Université catholique argentine
29 Hospital General Universitario "Gregorio Marañón" [Madrid]
30 Universidad de Sevilla = University of Seville = Université de Seville
31 Univerzita Palackého [Olomouci]
32 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
33 CHU Montpellier = Montpellier University Hospital
34 IGMM - Institut de Génétique Moléculaire de Montpellier
35 AP-HP - Hopital Saint-Louis [AP-HP]
36 Wrocław Medical University
37 Università del Salento = University of Salento [Lecce]
38 Unit of Melanoma Medical Oncology [Fondazione IRCCS Istituto Nazionale Tumori, Milan]
39 Universidad de Salamanca [España] = University of Salamanca [Spain]
40 Amsterdam UMC - Amsterdam University Medical Centers
41 Newcastle University [Newcastle]
42 DISIT - Dipartimento di Scienze e Innovazione Tecnologica [Alessandria]
43 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
44 Hospital Universitario Marqués de Valdecilla = Marqués de Valdecilla University Hospital [Santander]
45 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
46 Human Tumor Immunobiology Unit [Fondazione IRCCS Istituto Nazionale dei Tumori, Milan]
47 DEÜ - Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir]
48 UNIPR - Università degli studi di Parma = University of Parma
49 IPP PRAGUE - Institute of Plasma Physics, Association EURATOM
50 UFRJ - Universidade Federal do Rio de Janeiro [Brasil] = Federal University of Rio de Janeiro [Brazil] = Université fédérale de Rio de Janeiro [Brésil]
51 University of Belgrade [Belgrade]
52 Marmara University [Kadıköy - İstanbul]
53 UniBs - Università degli Studi di Brescia = University of Brescia
54 Universidad de Burgos = University of Burgos
55 Unicatt - Università cattolica del Sacro Cuore [Milano]
56 Uninsubria - Universitá degli Studi dell’Insubria = University of Insubria [Varese]
57 King‘s College London
58 UNIMI - Università degli Studi di Milano = University of Milan
59 UC San Diego - University of California [San Diego]
60 Universität zu Köln = University of Cologne
61 Clinique Turin
- Fonction : Auteur
- PersonId : 798377
- ORCID : 0000-0001-8287-928X
- Fonction : Auteur
- PersonId : 799544
- ORCID : 0000-0002-6766-8297
- Fonction : Auteur
- PersonId : 1168516
- ORCID : 0000-0002-7167-7882
- Fonction : Auteur
- PersonId : 781180
- ORCID : 0000-0002-6993-2450
- Fonction : Auteur
- PersonId : 825106
- ORCID : 0000-0003-0214-3219
- Fonction : Auteur
- PersonId : 814706
- ORCID : 0000-0002-5354-5261
- Fonction : Auteur
- PersonId : 825105
- ORCID : 0000-0002-3532-5281
- Fonction : Auteur
- PersonId : 814703
- ORCID : 0000-0001-6460-2471
- Fonction : Auteur
- PersonId : 1168517
- ORCID : 0000-0003-2461-5395
- Fonction : Auteur
- PersonId : 1168518
- ORCID : 0000-0002-7125-7001
- Fonction : Auteur
- PersonId : 1168519
- ORCID : 0000-0001-5809-7165
- Fonction : Auteur
- PersonId : 1168520
- ORCID : 0000-0002-5185-2073
- Fonction : Auteur
- PersonId : 825130
- ORCID : 0000-0002-1010-0975
- Fonction : Auteur
- PersonId : 825141
- ORCID : 0000-0001-8247-4901
- Fonction : Auteur
- PersonId : 1168521
- ORCID : 0000-0002-6486-8912
- Fonction : Auteur
- PersonId : 828120
- ORCID : 0000-0001-7502-8356
- Fonction : Auteur
- PersonId : 1168522
- ORCID : 0000-0003-0453-1709
- Fonction : Auteur
- PersonId : 825125
- ORCID : 0000-0002-3683-5953
- Fonction : Auteur
- PersonId : 1168523
- ORCID : 0000-0001-9630-9712
- Fonction : Auteur
- PersonId : 1168524
- ORCID : 0000-0003-4550-757X
- Fonction : Auteur
- PersonId : 814707
- ORCID : 0000-0002-4043-6613
- Fonction : Auteur
- PersonId : 799549
- ORCID : 0000-0002-9205-1440
- Fonction : Auteur
- PersonId : 745531
- IdHAL : sylvain-lamure
- ORCID : 0000-0001-5980-305X
- Fonction : Auteur
- PersonId : 805836
- ORCID : 0000-0001-9001-573X
- Fonction : Auteur
- PersonId : 1168525
- ORCID : 0000-0002-0270-3805
- Fonction : Auteur
- PersonId : 825128
- ORCID : 0000-0003-3161-3398
- Fonction : Auteur
- PersonId : 825121
- ORCID : 0000-0002-9901-0887
- Fonction : Auteur
- PersonId : 1168526
- ORCID : 0000-0002-0859-5550
- Fonction : Auteur
- PersonId : 797367
- ORCID : 0000-0001-7615-0572
- Fonction : Auteur
- PersonId : 1644078
- IdHAL : guillemettefouquet
- ORCID : 0000-0002-3751-393X
- Fonction : Auteur
- PersonId : 806771
- ORCID : 0000-0003-4867-0014
- Fonction : Auteur
- PersonId : 1168528
- ORCID : 0000-0002-8350-2182
- Fonction : Auteur
- PersonId : 1168529
- ORCID : 0000-0002-5097-591X
- Fonction : Auteur
- PersonId : 1168530
- ORCID : 0000-0001-7678-0179
- Fonction : Auteur
- PersonId : 806781
- ORCID : 0000-0002-9939-9298
- Fonction : Auteur
- PersonId : 795636
- ORCID : 0000-0002-8370-2248
- Fonction : Auteur
- PersonId : 825104
- ORCID : 0000-0003-0031-3237
- Fonction : Auteur
- PersonId : 769022
- ORCID : 0000-0001-8068-5289
- Fonction : Auteur
- PersonId : 814708
- ORCID : 0000-0003-2519-0333
- Fonction : Auteur
- PersonId : 769018
- ORCID : 0000-0002-9186-1353
- Fonction : Auteur
- PersonId : 765307
- ORCID : 0000-0002-1653-2824
- Fonction : Auteur
- PersonId : 797225
- ORCID : 0000-0001-9599-3137
Résumé
Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 2021 and March 2022 and registered in EPICOVIDEHA were included in this analysis. A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (p<0.001). In the multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone (p<0.001) or combined with antivirals (p=0.009), was observed protective. While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA (www.clinicaltrials.gov; National Clinical Trials identifier NCT04733729) is an international open web-based registry for patients with HMs infected with SARS-CoV-2.
Domaines
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|---|
| Licence |